Serum 8-hydroxy-2-deoxyguanosine levels in pediatric acute lymphoblastic leukemia: A retrospective case-control study.
In a retrospective case-control study of 32 children with acute lymphoblastic leukemia and 30 matched healthy controls, serum 8-OHdG was elevated before treatment and decreased after chemotherapy to levels not significantly different from controls.
Open original publication →What the AI sees
In a retrospective case-control study of 32 children with acute lymphoblastic leukemia and 30 matched healthy controls, serum 8-OHdG was elevated before treatment and decreased after chemotherapy to levels not significantly different from controls.
Research significance
The observed normalization of serum 8-OHdG after chemotherapy supports investigating it as a treatment-monitoring biomarker in pediatric ALL, but the supplied evidence does not establish that it predicts response, relapse, toxicity, or survival, nor does it support targeting oxidative stress therapeutically.
Source abstract
Oxidative stress contributes to carcinogenesis through deoxyribonucleic acid (DNA) damage, and 8-hydroxy-2-deoxyguanosine (8-OHdG) is a well-established biomarker of oxidative DNA injury. This study aimed to evaluate oxidative stress in pediatric acute lymphoblastic leukemia (ALL) by measuring serum 8-OHdG levels before and after chemotherapy. This retrospective case-control study included 32 children diagnosed with ALL and 30 age- and sex-matched healthy controls. Serum 8-OHdG levels were measured using an enzyme-linked immunosorbent assay prior to treatment and after the initiation of maintenance therapy, approximately one month following intensive chemotherapy. Comparisons between groups were performed using the Mann-Whitney U test, and within-patient changes were assessed using the Wilcoxon signed-rank test. Pretreatment serum 8-OHdG levels were significantly higher in children with ALL compared with controls (P < .001), indicating increased oxidative DNA damage. Serum 8-OHdG levels significantly decreased after chemotherapy in children with ALL (P < .001). However, no statistically significant difference was observed between post-treatment 8-OHdG levels and those of the control group (P = 1.0). No significant associations were found between pretreatment 8-OHdG levels and white blood cell count or body mass index. Children with ALL exhibit significantly elevated serum 8-OHdG levels, supporting a role for oxidative stress in disease pathogenesis. The reduction in 8-OHdG levels following chemotherapy suggests a potential relationship between treatment response and oxidative DNA damage, indicating that 8-OHdG may serve as a useful biomarker in pediatric ALL.